Skip to Main Content

Another effort by Vital Therapies (VTL) to transform plastic tubes into a lifesaving artificial liver ended in disappointment Wednesday. And after this latest setback, the company has decided to give up.

Liver failure patients hooked up to Vital’s biomedical device, called the ELAD System, did not live any longer than similar patients treated with standard therapy — failing to meet the main goal of a Phase 3 clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!